Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Raised to $760.00

Madrigal Pharmaceuticals (NASDAQ:MDGL) had its target price boosted by Citigroup from $725.00 to $760.00 in a research report released on Tuesday morning,Benzinga reports. Citigroup currently has a buy rating on the biopharmaceutical company’s stock.

Other research analysts also recently issued research reports about the company. UBS Group reaffirmed a “buy” rating and set a $735.00 price objective on shares of Madrigal Pharmaceuticals in a report on Wednesday, October 14th. Barclays lowered their target price on Madrigal Pharmaceuticals from $964.00 to $962.00 and set an “overweight” rating for the company in a research note on Monday, August 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a research report on Thursday, October 15th. Wolfe Research raised Madrigal Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $605.00 price target on the stock in a research note on Tuesday, August 4th. Finally, The Goldman Sachs Group began coverage on Madrigal Pharmaceuticals in a report on Thursday, September 24th. They issued a “buy” rating and a $704.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Madrigal Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $706.87.

Madrigal Pharmaceuticals Price Performance

Shares of NASDAQ MDGL opened at $400.10 on Tuesday. Madrigal Pharmaceuticals has a 1-year low of $353.54 and a 1-year high of $615.00. The company has a 50-day moving average of $489.63 and a two-hundred day moving average of $497.94. The company has a quick ratio of 2.94, a current ratio of 3.05 and a debt-to-equity ratio of 0.54.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 EPS for the quarter, beating the consensus estimate of ($1.09) by $2.92. The business had revenue of $431.27 million for the quarter, compared to analysts’ expectations of $404.17 million. Madrigal Pharmaceuticals had a negative net margin of 10.89% and a negative return on equity of 27.08%. During the same period in the prior year, the firm earned ($5.08) earnings per share. On average, equities research analysts expect that Madrigal Pharmaceuticals will post -6.88 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO William Sibold sold 6,362 shares of the business’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $535.59, for a total value of $3,407,423.58. Following the completion of the transaction, the chief executive officer owned 202,967 shares of the company’s stock, valued at $108,707,095.53. The trade was a 3.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Shannon Kelley sold 664 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $514.97, for a total transaction of $341,940.08. Following the completion of the sale, the general counsel owned 11,474 shares of the company’s stock, valued at approximately $5,908,765.78. This represents a 5.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 12,247 shares of company stock worth $6,581,182. Insiders own 17.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Concurrent Investment Advisors LLC boosted its stake in Madrigal Pharmaceuticals by 2.0% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 1,034 shares of the biopharmaceutical company’s stock worth $555,000 after purchasing an additional 20 shares during the period. Fifth Third Bancorp raised its stake in shares of Madrigal Pharmaceuticals by 3.5% in the 3rd quarter. Fifth Third Bancorp now owns 838 shares of the biopharmaceutical company’s stock valued at $422,000 after purchasing an additional 28 shares during the period. Commonwealth Equity Services LLC raised its stake in shares of Madrigal Pharmaceuticals by 2.7% in the 3rd quarter. Commonwealth Equity Services LLC now owns 1,664 shares of the biopharmaceutical company’s stock valued at $839,000 after purchasing an additional 43 shares during the period. ProShare Advisors LLC raised its stake in shares of Madrigal Pharmaceuticals by 5.5% in the 3rd quarter. ProShare Advisors LLC now owns 838 shares of the biopharmaceutical company’s stock valued at $422,000 after purchasing an additional 44 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in shares of Madrigal Pharmaceuticals by 35.4% in the second quarter. GAMMA Investing LLC now owns 172 shares of the biopharmaceutical company’s stock valued at $92,000 after purchasing an additional 45 shares in the last quarter. 98.50% of the stock is owned by institutional investors and hedge funds.

Key Madrigal Pharmaceuticals News

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: New real-world findings presented at AASLD 2026 reported improvements in liver stiffness and cardiometabolic health markers among Rezdiffra-treated patients across multiple studies. The data may reinforce confidence in the drug’s real-world benefits and commercial potential. Article: Madrigal Announces New Real-World Data
• Positive Sentiment: Recent quarterly results showed a swing to profitability, with EPS of $1.83 versus analysts’ expected loss of $1.09 and revenue of $431.3 million, above estimates. Rezdiffra sales had surpassed $1.1 billion, underscoring uptake of the company’s main product. Article: Madrigal’s MASH Drug Shows Improvements
• Positive Sentiment: Analyst support remains favorable: Canaccord raised its price target to $633 and Truist lifted its target to $743, both maintaining Buy ratings. HC Wainwright also assigned a Strong Buy rating. These views point to expectations for continued growth, though analyst targets are not guarantees. Article: Canaccord Genuity Group Recommendations
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations involving Madrigal, adding headline risk and potential investor concern. These are investigations, not findings of wrongdoing. Article: Law Offices of Frank R. Cruz Investigation Article: Kaplan Fox Investigation

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for nonalcoholic steatohepatitis, now known as metabolic dysfunction-associated steatohepatitis (MASH), and other chronic liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal’s lead product is Rezdiffra (resmetirom), an orally administered thyroid hormone receptor beta agonist designed to target key drivers of liver disease, including hepatic fat accumulation and fibrosis.